Izalontamab Brengitecan in Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: The PANKU-Esophagus01 Randomized Clinical Trial
Importance: Effective therapy remains lacking for patients with advanced esophageal squamous cell carcinoma (ESCC) whose disease progressed after standard treatment. Izalontamab brengitecan, an epidermal growth factor receptor and human epidermal growth factor receptor 3 bispecific antibody-drug conjugate with a topoisomerase I inhibitor, Ed-04, has shown clinical activity in ESCC in a phase 1b study. Objective: To evaluate the efficacy and safety of izalontamab brengitecan compared with chemotherapy in patients with advanced ESCC who progressed after first-line programmed cell death 1 protein (PD-1)/programmed cell death 1 ligand 1 (PD-L1) inhibitor plus platinum-containing chemotherapy. Design, Setting, and Participants: This phase 3, open-label, randomized clinical trial was conducted across 80 hospitals in China. Patients with recurrent or metastatic ESCC that had progressed with first-line PD-1/PD-L1 inhibitor plus platinum-containing chemotherapy were enrolled. Between March 19, 2024, and August 1, 2025 (final follow-up, October 17, 2025), a total of 704 patients were screened, and 497 were enrolled and randomized. Interventions: Patients were randomly assigned (1:1) to receive either izalontamab brengitecan (n = 249; 2.5 mg/kg on days 1 and 8 every 3 weeks) or physician-selected chemotherapy (n = 248; irinotecan, paclitaxel, or docetaxel) every 3 weeks. Main Outcomes and Measures: The dual primary end points were progression-free survival (PFS) assessed by blinded independent central review according to Response Evaluation Criteria in Solid Tumors version 1.1 and overall survival (OS). Results: Of 497 patients who underwent randomization (median age, 61.0 years [range, 34-76]; 448 male patients [90.1%]), 493 received study treatment. At this interim analysis, izalontamab brengitecan demonstrated statistically significant improvement in both PFS and OS. Median PFS by blinded independent central review was 4.17 months (95% CI, 3.61-4.53 months) with izalontamab brengitecan vs 1.97 months (95% CI, 1.61-2.73 months) with chemotherapy (hazard ratio, 0.50; 95% CI, 0.40-0.63; log-rank P < .001). Median OS was 9.79 months (95% CI, 7.89-11.01 months) with izalontamab brengitecan vs 7.20 months (95% CI, 6.18-7.82 months) with chemotherapy (hazard ratio, 0.63; 95% CI, 0.48-0.82; log-rank P < .001). Grade 3 or higher treatment-related adverse events occurred in 212 of 249 patients (85.1%) with izalontamab brengitecan and 147 of 248 patients (59.3%) with chemotherapy and were predominantly hematologic. Conclusions and Relevance: Izalontamab brengitecan significantly improved PFS and OS vs chemotherapy in patients with recurrent or metastatic ESCC whose disease had progressed after first-line treatment. These findings support izalontamab brengitecan as a new second-line treatment for this population in China. Trial Registration: ClinicalTrials.gov Identifier: NCT06304974.
Authors
- X. Meng (ORCID: https://orcid.org/0000-0003-2737-5905)
- Yong Gao (ORCID: https://orcid.org/0000-0001-7812-0932)
- Yongli Gao (ORCID: https://orcid.org/0000-0001-8012-7674)
- Jiangqiong Huang
- Jun Wang (ORCID: https://orcid.org/0000-0002-9733-1433)
- Shoubing Zhou (ORCID: https://orcid.org/0000-0003-1080-7396)
- Jianping Xiong (ORCID: https://orcid.org/0000-0003-0398-6090)
- Jun Bie (ORCID: https://orcid.org/0000-0002-8296-0544)
- Zhixiang Zhan
- Yonghui Di (ORCID: https://orcid.org/0009-0006-0056-8933)
- 锁爱莉
- Shubo Ding (ORCID: https://orcid.org/0009-0003-2217-8205)
- Qingsong Pang (ORCID: https://orcid.org/0000-0002-3576-6909)
- Yarong Li (ORCID: https://orcid.org/0009-0004-7240-6453)
- Zheng Liu (ORCID: https://orcid.org/0000-0002-3538-9349)
- Feng Ye
- Yun Fan (ORCID: https://orcid.org/0000-0003-1755-0175)
- Fang Ma (ORCID: https://orcid.org/0000-0003-1116-0467)
- Wei Ren (ORCID: https://orcid.org/0000-0002-1061-276X)
- Jinglei Qu
- Guochun Cao
- Tienan Yi (ORCID: https://orcid.org/0009-0008-8678-4841)
- Na Li (ORCID: https://orcid.org/0000-0001-6361-8463)
- Lixin Wan (ORCID: https://orcid.org/0009-0003-2240-7397)
- Zishu Wang
- Yong Fang
- Zhenhua Liu
- Ruiqiang Ma
- Jun Guo
- Xuwei Cai
- Zhangzhou Huang
- Haifeng Liu
- Guohua Yu
- Tao Wu
- Hongming Pan
- Yuhua Chi
- Yanhong Gu
- Yi Peng
- Hui Luo
- Yi Jiang
- Jianzhong Cao
- Shegan Gao
- Min Shi
- Meili Sun
- Lin Shen
- Zhihao Lu
- Jin Zhou
- Yinghua Ji
- Jingdong Zhang
- Yu Liu
- Shouguo Li
- Xicheng Wang
- Xiaobing Han
- Jiayan Chen
- Ning Li
- Yueyin Pan
- Feng Wang
- Mingjun Zhang
- Xiaotian Zhang
- Li Zhang
- Yanru Qin
- Yanqiao Zhang
- Jing Lu
- PANKU-Esophagus01 Investigators
- Jianfei Fu
- Yan Luo
- Xueqiang Zhu
- Daiyuan Ma
- Yan Yang
- Jianfei Tu
- Wei Li
- Liying Zhu
- Buhai Wang
- Dong Yan
- Xuelei Ma
- Zhenyang Liu
- Wenbin Yue
- Wenhui Yang
- Liying Xue
- Sa Xiao
- Gaofeng Li
- Yu Zhang
- Hai Zhu
- Yi Zhu
- Qingshan Li
- Jun Zhao
- Tiejun Ren
- Junye Wang
- Tianshu Liu
- Yong Xin
Institutions
- University of Science and Technology of China (CN)
- Fujian Medical University (CN)
- University of Electronic Science and Technology of China (CN)
- Chongqing University (CN)
- Guangxi Medical University (CN)
- Henan University of Science and Technology (CN)
- Shanxi Medical University (CN)
- Shanghai Jiao Tong University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Sichuan University (CN)
- Fudan University (CN)
- Sir Run Run Shaw Hospital (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Shanghai Chest Hospital (CN)
- Wuhan University (CN)
- Zhengzhou University (CN)
- First Affiliated Hospital of Xiamen University (CN)
- West China Hospital of Sichuan University (CN)
- Fudan University Shanghai Cancer Center (CN)
- Peking University Cancer Hospital (CN)
- Jiangxi Provincial Cancer Hospital (CN)
- Linyi People's Hospital (CN)
- Zhejiang Cancer Hospital (CN)
- Shandong Tumor Hospital (CN)
- Shanxi Provincial Cancer Hospital (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Fourth Hospital of Hebei Medical University (CN)
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (CN)
- Sichuan Cancer Hospital (CN)
- Xiangyang Central Hospital (CN)
- Zhongnan Hospital of Wuhan University (CN)
- First Hospital of Jilin University (CN)
- Zhongshan Hospital (CN)
- Jiangsu Cancer Hospital (CN)
- First Affiliated Hospital of Henan University of Science and Technology (CN)
- First Hospital of China Medical University (CN)
- Henan Cancer Hospital (CN)
- Fujian Provincial Cancer Hospital (CN)
- Second Affiliated Hospital of Anhui Medical University (CN)
- Jiangsu Province Hospital (CN)
- Second Xiangya Hospital of Central South University (CN)
- Chongqing Cancer Hospital (CN)
- Tumor Hospital of Guangxi Medical University (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Liaoning Cancer Hospital & Institute (CN)
- Anyang Tumor Hospital (CN)
- Shandong First Medical University (CN)
- First Affiliated Hospital of Nanchang University (CN)
- State Key Laboratory of Biotherapy (CN)
- State Key Laboratory of Proteomics (CN)
- Sichuan Baili Pharmaceutical Co., Ltd. (China) (CN)
- Inner Mongolia Medical University (CN)
- Zhejiang University (CN)
- Henan Medical University (CN)
- Fuzhou University (CN)
Publication Details
- Journal
- JAMA
- Published
- 2026-11-12
- DOI
- https://doi.org/10.1001/jama.2026.20250
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00